ARCA BIOPHARMA INC (ABIO) Fundamental Analysis & Valuation

NASDAQ:ABIO • US00211Y5069

Current stock price

2.4 USD
-0.1 (-4%)
At close:
2.48 USD
+0.08 (+3.33%)
After Hours:

This ABIO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ABIO Profitability Analysis

1.1 Basic Checks

  • ABIO had negative earnings in the past year.
  • ABIO had a negative operating cash flow in the past year.
  • In the past 5 years ABIO always reported negative net income.
  • ABIO had a negative operating cash flow in each of the past 5 years.
ABIO Yearly Net Income VS EBIT VS OCF VS FCFABIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M

1.2 Ratios

  • ABIO has a Return On Assets of -21.27%. This is in the better half of the industry: ABIO outperforms 77.82% of its industry peers.
  • ABIO has a Return On Equity of -22.10%. This is amongst the best in the industry. ABIO outperforms 85.21% of its industry peers.
Industry RankSector Rank
ROA -21.27%
ROE -22.1%
ROIC N/A
ROA(3y)-24.11%
ROA(5y)-31.22%
ROE(3y)-25.36%
ROE(5y)-33.83%
ROIC(3y)N/A
ROIC(5y)N/A
ABIO Yearly ROA, ROE, ROICABIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ABIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABIO Yearly Profit, Operating, Gross MarginsABIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. ABIO Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, ABIO has more shares outstanding
  • ABIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ABIO Yearly Shares OutstandingABIO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M
ABIO Yearly Total Debt VS Total AssetsABIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

  • An Altman-Z score of 8.70 indicates that ABIO is not in any danger for bankruptcy at the moment.
  • ABIO's Altman-Z score of 8.70 is amongst the best of the industry. ABIO outperforms 84.33% of its industry peers.
  • ABIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.7
ROIC/WACCN/A
WACCN/A
ABIO Yearly LT Debt VS Equity VS FCFABIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M

2.3 Liquidity

  • A Current Ratio of 26.61 indicates that ABIO has no problem at all paying its short term obligations.
  • The Current ratio of ABIO (26.61) is better than 95.95% of its industry peers.
  • ABIO has a Quick Ratio of 26.61. This indicates that ABIO is financially healthy and has no problem in meeting its short term obligations.
  • ABIO has a Quick ratio of 26.61. This is amongst the best in the industry. ABIO outperforms 95.95% of its industry peers.
Industry RankSector Rank
Current Ratio 26.61
Quick Ratio 26.61
ABIO Yearly Current Assets VS Current LiabilitesABIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. ABIO Growth Analysis

3.1 Past

  • The earnings per share for ABIO have decreased strongly by -13.18% in the last year.
EPS 1Y (TTM)-13.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-79.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ABIO Yearly EPS VS EstimatesABIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2024 2025 2026 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

0

4. ABIO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ABIO. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABIO Price Earnings VS Forward Price EarningsABIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABIO Per share dataABIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. ABIO Dividend Analysis

5.1 Amount

  • ABIO has a Yearly Dividend Yield of 67.21%, which is a nice return.
  • The stock price of ABIO dropped by -35.14% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
  • ABIO's Dividend Yield is rather good when compared to the industry average which is at 1.30. ABIO pays more dividend than 99.82% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.89, ABIO pays a better dividend.
Industry RankSector Rank
Dividend Yield 67.21%

5.2 History

  • ABIO is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
ABIO Yearly Dividends per shareABIO Yearly Dividends per shareYearly Dividends per share 2024 5 10 15

5.3 Sustainability

DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
ABIO Yearly Income VS Free CF VS DividendABIO Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M

More info and screens

Find the best dividend stocksShow peers with best dividend

ABIO Fundamentals: All Metrics, Ratios and Statistics

ARCA BIOPHARMA INC

NASDAQ:ABIO (8/30/2024, 8:00:00 PM)

After market: 2.48 +0.08 (+3.33%)

2.4

-0.1 (-4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31
Earnings (Next)10-16
Inst Owners0.05%
Inst Owner Change0%
Ins Owners61.11%
Ins Owner Change0%
Market Cap34.82M
Revenue(TTM)N/A
Net Income(TTM)-7.20M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 67.21%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.07
P/tB 1.07
EV/EBITDA N/A
EPS(TTM)-0.5
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.47
OCFYN/A
SpS0
BVpS2.24
TBVpS2.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.27%
ROE -22.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.11%
ROA(5y)-31.22%
ROE(3y)-25.36%
ROE(5y)-33.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 26.61
Quick Ratio 26.61
Altman-Z 8.7
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)92.92%
Cap/Depr(5y)95.75%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-79.73%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-16.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.85%
OCF growth 3YN/A
OCF growth 5YN/A

ARCA BIOPHARMA INC / ABIO Fundamental Analysis FAQ

What is the fundamental rating for ABIO stock?

ChartMill assigns a fundamental rating of 3 / 10 to ABIO.


What is the valuation status for ABIO stock?

ChartMill assigns a valuation rating of 0 / 10 to ARCA BIOPHARMA INC (ABIO). This can be considered as Overvalued.


Can you provide the profitability details for ARCA BIOPHARMA INC?

ARCA BIOPHARMA INC (ABIO) has a profitability rating of 1 / 10.


Can you provide the financial health for ABIO stock?

The financial health rating of ARCA BIOPHARMA INC (ABIO) is 8 / 10.